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Background: Ovarian cancer is a common gynaecological malignancy still remaining a challenge to treat. The
objective of this study was to evaluate the impact of platinum dose reduction and chemotherapy delays on
progression free survival and overall survival in patients with stage III ovarian cancer and to analyze reasons for such
chemotherapy scheme modifications.
Methods: Medical records of patients with FIGO stage III ovarian cancer were reviewed. Inclusion criteria involved
FIGO stage III epithelial ovarian carcinoma; cytoreductive surgery performed and 6 courses of platinum-based
chemotherapy completed; no neoadjuvant chemotherapy applied; and no history of previous malignancies.
Progression free survival and overall survival were analyzed using Kaplan-Meier and Cox proportional hazards
models.
Results: Significant 3.3 times higher death risk in patients who experienced only chemotherapy delays compared
with patients who did not experience any chemotherapy scheme modifications was established (HR = 3.3, 95% Cl:
1.2 – 8.5, p = 0.016). Increased death risk in patients who experienced only chemotherapy delays compared with
patients who experienced both chemotherapy delays and platinum dose reduction was also established (HR = 2.3,
95% Cl: 1.1 – 4.8, p = 0.021). Main reasons for chemotherapy scheme modifications (in decreasing order) were the
following: neutropenia, modifications with no objective medical reasons, renal disorders, anaemia, poor
performance status, gastrointestinal symptoms and neuropathy. Overall survival in patients who experienced
chemotherapy scheme modifications with no objective medical reasons was non-inferior than in patients who did
not experience any chemotherapy scheme modifications.
Conclusions: Chemotherapy delays in patients with FIGO stage III ovarian cancer caused lower overall survival. The
most common reason for chemotherapy scheme modifications was neutropenia.
Keywords: Ovarian cancer, Chemotherapy scheme modifications, Progression free survival, Overall survivalBackground
Ovarian cancer is the fifth most common malignant
tumor in females and the forth most common cause of
female deaths from malignant tumors in the world [1].
In 2012 in Europe 65 538 new ovarian cancer cases were
diagnosed and 42 704 deaths from ovarian cancer were
registered. Meanwhile Lithuania ranks 5th among all* Correspondence: sigitaliu@yahoo.com
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unless otherwise stated.European countries (incidence is 16.2 cases/100 000 fe-
males and mortality is 11.9/100 000 females) [2]. Early
diagnosis of ovarian cancer is still difficult due to ab-
sence of specific clinical signs or asymptomatic course of
the disease therefore advanced cancer is being diagnosed
in majority of patients [3]. Association between the
diameter of the postoperative residual tumor mass and
survival was first discovered by C. T. Griffths in 1975 [4]
and later proved by other studies [5,6] and these findings
were the cornerstone of the progress in ovarian cancer
treatment. Progress in treatment was also essentiallyentral. This is an Open Access article distributed under the terms of the Creative
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iveness of various chemotherapy schemes carried out in
the recent decades resulting in employing platinum -
based adjuvant chemotherapy as main method of sys-
temic treatment of advanced ovarian cancer [7]. Despite
the fact that disease progression after primary chemo-
therapy is observed in approximately two thirds of pa-
tients [8], five-year survival rate is improving from 5–
17% decades ago to 48% and more nowadays according
to some researchers [9]. According to the data of the
Nordic countries obtained during 40 years observation
period survival rates of women with ovarian cancer im-
proved 10–15% from 1964 to 2003 [10]. Impact of
tumor stage, histology, grade and patients’ age on clinical
outcomes is well established [11,12]; however few studies
analyzed impact of chemotherapy delays and dose reduc-
tion on progression free survival and overall survival
[13]. Therefore the purpose of this study is to establish
influence of platinum dose reduction and chemotherapy
delays on progression free survival and overall survival
in women with stage III ovarian cancer and to analyze
reasons for such chemotherapy scheme modifications.
Methods
This study was approved by the Bioethics Center of
Lithuanian University of Health Sciences. Medical re-
cords of patients with International Federation of
Gynecology and Obstetrics (FIGO) stage III ovarian
cancer treated in the Afilliate of Lithuanian University
of Health Sciences Kaunas Oncology Hospital were
analyzed.
Inclusion criteria of the study were the following: 1)
patients with FIGO stage III epithelial ovarian carcinoma
diagnosed in 2004–2008; 2) cytoreductive surgery per-
formed and 6 courses of platinum-based chemotherapy
completed; 3) medical records maintain comprehensive
data on treatment and follow-up; 4) no history of previ-
ous malignancies. Exclusion criteria were the following:
1) neoadjuvant chemotherapy applied; 2) less than 6
courses of chemotherapy or more than 6 courses of
chemotherapy completed; 3) medical records maintain
incomplete data on treatment or follow-up; 4) history of
previous malignancy.
Among all patients treated with platinum – based
chemotherapy only those who received 6 courses were
selected, because usually 6 cycles of treatment is recom-
mended as a standard regimen; what is more this deci-
sion was taken in order to avoid possible differences in
patients outcomes influenced by unequal number of
chemotherapy cycles given.
The process of cases selection is shown in Figure 1.
The following data necessary for this study were col-
lected: patients age at the time of diagnosis, height and
weight, tumor histology and grade, date of cytoreductivesurgery, date of disease progression, date of last visit,
date of death. Platinum response status was evaluated
(platinum resistant tumor: disease progression occurred
within 6 months after completion of primary chemother-
apy; platinum sensitive tumor: disease progression oc-
curred after more than 6 months after completion of
primary chemotherapy). Platinum dose reduction was
defined as overall dose reduction more than 5 percent;
chemotherapy delays were defined as number of delayed
days exceeding 10 days. 5 percent as the cutoff for dose
reduction and 10 days as the cutoff for the delay were
defined because such were minimal modifications ob-
served in our study. Reason for every single platinum
dose reduction and chemotherapy delay was established.
It should be noted that no granulocyte colony stimulat-
ing factors were administered to patients under
investigation.
Statistical analysis
The major goals of the study were to assess the impact
of platinum dose reduction and chemotherapy delays on
survival outcomes – progression free survival (PFS) and
overall survival (OS). PFS was defined as a period be-
tween the date of cytoreductive surgery and date when
tumor progression was defined or date of the last known
follow up for patients without disease progression. OS
was defined as the duration between the date of cytore-
ductive surgery and death, with those alive censored at
the last known follow up.
The Kaplan-Meier method was used for single variable
survival data analysis. Differences of the survival rate
were determined using the log-rank test.
Cox’s proportional hazards regression model was used
to conduct multivariate analysis. The proportional haz-
ards assumption was examined by log (−log) plot of sur-
vival. The results are presented as medians of survival,
HR and 95% confidence intervals.
Comparison among subgroups was performed using
ANOVA for continuous covariates and Fisher’s exact test
for categorical variables.
Level of significance for statistical tests was 0.05. All
p - values presented are two – sided. The SPSS software
version 22 was used for statistical analysis.
Results
Eighty-two eligible patients were analyzed. For all pa-
tients median progression free survival was 15.4 months
(95% Cl: 9.3 - 21.4 months), and median overall survival
was 32.1 months (95% Cl: 25.5 – 38.7 months).
Patients were divided into four chemotherapy delay/
platinum reduction groups. There was no platinum dose
reduction or chemotherapy delays in 15 patients (18.3%).
In 67 patients (81.7%) chemotherapy scheme was modi-
fied: 11 patients (13.4%) experienced only platinum dose
Figure 1 Flow chart of cases used for analysis. The whole process of identification of the patients that meet study criteria is shown in this
chart. 82 patients were used for final analysis.
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therapy delays and 44 patients (53.7%) experienced both
platinum dose reduction and chemotherapy delays.
Age at the time of diagnosis was significantly different
in these four groups (p = 0.001); other characteristics
were similar (Table 1).
The impact of patients' age, BMI, tumor grade, hist-
ology and platinum response status to overall survival
was tested conducting univariate Cox analysis. All these
variables except BMI were proved to have a possible
prognostic significance (p < 0.35) in univariate analysis
and were adopted as covariates in multivariate Cox pro-
portional risk model. Results of this analysis for overall
survival are presented in Table 2.
This Cox proportional hazards model for overall sur-
vival with adjustment for patients’ age, tumor grade,
histology and platinum response status revealed statisti-
cally significant overall survival difference in patients
who experienced only chemotherapy delays compared
with patients who did not experience neither chemo-
therapy delays nor platinum dose reduction, e. g., deathrisk was 3.3 times higher in patients who experienced
only chemotherapy delays compared with patients who
did not experience any modifications (HR = 3.3, 95% Cl:
1.2 – 8.5, p = 0.016). Significantly increased death risk in
patients who experienced only chemotherapy delays
compared with patients who experienced both chemo-
therapy delays and platinum dose reduction was also
established (HR = 2.3, 95% Cl: 1.1 – 4.8, p = 0.021).
Survival curves for overall survival adjusted for pa-
tients’ age, tumor grade, histology and platinum re-
sponse status is shown in Figure 2.
According to Cox proportional hazards model for pro-
gression free survival constructed identically to above-
mentioned model, there were no statistically significant
differences of progression free survival between the same
four patients groups, the overall p = 0.35.
Median progression free survival and median overall
survival in these groups are presented in Table 3.
This study showed that main reasons for chemother-
apy scheme modifications were the following: neutro-
penia (37.5%), renal disorders (15.6%), anaemia (10.9%),





Delays only Both Platinum
reduction and delays
(N = 15) (N = 11) (N = 12) (N = 44)
Age, mean (range) 46.6 (22–67) 52.0 (42–65) 60.8 (42–82) 59.7 (40–82)
BMI, mean (range) 24.9 (16.1–46.1) 25.1 (18.2–33.7) 26.5 (19.5–39.5) 26.9 (16.7–38.2)
(kg/m2)
Histology
Serous 13 (86.6%) 11 (100%) 10 (83.4%) 32 (72.7%)
Mucinous 1 (6.7%) 0 (0%) 1 (8.3%) 4 (9.1%)
Endometrioid 0 (0%) 0 (0%) 1 (8.3%) 1 (2.3%)
Clear cell 0 (0%) 0 (0%) 0 (0%) 2 (4.5%)
Mixed 1 (6.7%) 0 (0%) 0 (0%) 5 (11.4)
Tumor grade
Grade 1 0 (0%) 1 (9.1%) 1 (8.3%) 6 (13.6%)
Grade 2 11 (73.3%) 8 (72.7%) 9 (75.0%) 24 (54.6%)
Grade 3 4 (26.7%) 2 (18.2%) 2 (16.7%) 14 (31.8%)
(N = 82).
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toms (4.7%), and neuropathy (1.6%). Modifications with
no objective medical reason accounted for 25.0%.
(Figure 3). When medical records contained no medical
reason that could predetermine platinum dose reduction
or chemotherapy delay, such modification was consid-
ered to have no objective medical reason. Considering
this reason was the second most frequent among all rea-






Platinum response status (resistant versus sensitive) 3.412 2.002
Chemoterapy scheme modification
No Platinum reduction or delay 1
Both Platinum reduction and delay 1.380 0.658
Platinum reduction only 1.388 0.550
Delay only 3.359 1.375





histology (serous versus other) 1.393 0.706
BMI 1.012 0.973
Delay only versus both reduction and delaysurvival curve of patients who experienced modifications
without objective medical reasons was compared with
overall survival curve of patients who had no modifica-
tions. Using Kaplan-Meier method it was not proved
that chemotherapy scheme modifications without object-
ive medical reason caused lower overall survival com-
pared with patients who had no chemotherapy scheme
modifications, long-rank test p = 0.815. When chemo-
therapy scheme was modified with no objective medicaloverall survival
Multivariate model
r Exp (B) p Exp
(B)
95.0% CI for Exp (B) p
Upper Lower Upper
5.817 <0.001 3.169 1.787 5.620 <0.001
0.035 0.050
1
2.896 0.394 1,404 0.615 3.205 0.420
3.500 0.487 2,054 0.755 5.586 0.159
8.204 0.008 3.262 1.248 8,527 0.016
2.115 0.130 1.547 0.936 2.556 0.089
0.225 0.260
1
1.805 0.945 0.723 0.362 1.445 0.359
2.926 0.135 1.327 0.653 2.695 0.434
2.750 0.339 1.076 0.518 2.234 0.844
1.053 0.539
HR p
2.323 1.135 4.753 0.021
Figure 2 Overall survival: adjusted for age, tumor grade, histology and platinum response status. Cox proportional hazards model when
impact of tumor histology, grade, patients’ age and platinum response status were adjusted showed that death risk was 3.3 times higher in patients
who experienced only chemotherapy delays compared with patients who experienced no chemotherapy delays or platinum dose reduction (HR = 3.3,
95% Cl: 1.2 – 8.5, p = 0.016) and also showed that death risk was 2.3 times higher in patients who experienced only chemotherapy delays compared
with patients who experienced both chemotherapy delays and platinum dose reduction (HR = 2.3, 95% Cl: 1.1 – 4.8, p = 0.021).
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(95% Cl: 16.7 - 36.2 months) and median overall survival
was 51.2 months (95% Cl: 23.4 - 78.9 months).
Discussion
The main objective of this study was to evaluate impact
of the optimum first-line chemotherapy on clinical out-
comes of patients with FIGO stage III ovarian cancer.
Although many previous studies analyzing effect of
chemotherapy schemes intensity on survival did not es-
tablish any advantages of more intense treatment com-
pared with less intense treatment [14-16], an impact of
modifications of standard chemotherapy schemes, e.g.,Table 3 Unajusted median progression free and overall
survival (95% Cl)
N PFS (months) OS (months)
No platinum
reduction or delays
15 15.4 (9.3 – 21.4) 35.8 (16.1 – 55.6)
Platinum reduction only 11 13.1 (10.7 – 34.5) 28.8 (20.5 – 37.2)
Delays only 12 10.8 (4.2 – 17.4) 15.8 (11.9–19.8)
Both Platinum reduction
and delays
44 18.3 (10.9 – 25.7) 39.6 (26.2 – 52.4)dose reduction and chemotherapy delays, on survival
outcomes is still unclear because results of similarly de-
signed studies are contradictory. To characterize modifi-
cations of chemotherapy schemes, the term relative dose
intensity (RDI) is also used in scientific literature; RDI is
calculated as delivered dose intensity (total delivered
dose divided by actual time required to complete ther-
apy) divided by standard dose intensity (standard dose
divided by planned time to complete therapy). The im-
pact of both factors forming the concept of RDI, i.e.,
dose reduction and chemotherapy delays, on survival
were analyzed in our study. C. I. Nagel et al. did not es-
tablish statistically significant survival difference between
patients who underwent modifications of chemotherapy
scheme and those that did not [13]. However J. M. Fauci
et al. in their study on the effect of RDI for the efficacy
of treatment of all stages of ovarian cancer make a con-
clusion that dose reduction and chemotherapy delays are
important prognostic factors for survival and these mod-
ifications should be minimized [17]. R. K. Hanna et al.
present similar results: reduced RDI exerted negative ef-
fect on overall survival of patients with stage III-IV ovar-
ian cancer. No impact of chemotherapy scheme
modifications on progression free survival was found in
Figure 3 Reasons for chemotherapy scheme modifications. Reason for every single platinum dose reduction and chemotherapy delay was
established. The most common of them from most to least frequent were neutropenia, modifications with no objective medical reasons, renal
disorders, anaemia, poor performance status, gastrointestinal (GI) symptoms and neuropathy.
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our study demonstrates the same result. It was estab-
lished in our study that death risk was statistically sig-
nificant 3.3 times higher (p = 0.016) in patients who
experienced only chemotherapy delays compared with
patients who did not experience any chemotherapy
scheme modifications. These results essentially confirm
conclusions of aforementioned studies carried out by J.
M. Fauci et al. and R. K. Hanna et al. concerning nega-
tive impact of chemotherapy scheme modifications on
patients overall survival. However, our study also estab-
lished 2.3 times higher death risk (p = 0.021) in patients
who experienced only chemotherapy delays compared
with patients who experienced both chemotherapy de-
lays and platinum dose reduction. This result was unex-
pected for us because it means that extension of the
intervals between chemotherapy courses (extends also
overall duration of chemotherapy) without dose reduc-
tion may predetermine shorter overall survival in pa-
tients with FIGO stage III ovarian cancer. Such trend
could be caused by the toxicity of chemotherapy related
to patient’s individual sensitivity to chemotherapy. This
result confirms the general principle of optimum
chemotherapy: when grade III-IV adverse reaction oc-
curs, chemotherapeutic drugs dose must be reduced by
20–25 percent due to threatening complications or ad-
verse reactions to chemotherapy should be managed and
treated appropriately. It should be emphasized that main
reason for chemotherapy scheme modifications in our
study was neutropenia, and colony-stimulating factors
were not administered to patients of our study. On the
other hand, similar study on RDI significance for clinical
outcomes in patients with metastatic breast cancer car-
ried out by S. Loibl et al. also showed an unexpectedresult: optimal RDI was related to shorter progression
free survival. This result was associated with early pro-
gression of the disease when disease progression or pa-
tient death occurred before 3rd course of chemotherapy.
When data of early disease progression were excluded
from the analysis, positive optimum RDI impact on
overall survival was established [19]. However, publica-
tion authors do not indicate how many patients died be-
fore 3rd course of chemotherapy and what were the
causes of deaths; these deaths could be possibly caused
by chemotherapy toxic effects. It is clear today that clin-
ical study participants are usually patients with better
performance status without concomitant diseases or
with clinically insignificant concomitant diseases, and
therefore optimum chemotherapy treatment is adminis-
tered to these patients. However, in everyday clinical
practice chemotherapy dose reduction and chemother-
apy delays are frequent, and previous surgery, doctor’s
experience, adequate assessment of patients’ perform-
ance status, other treatment lines and many social fac-
tors affects clinical outcomes. It is also worth to state
that in our study in all patients who experienced chemo-
therapy delays total number of delayed days exceeded
10 days and this factor could contribute lower survival
as in C. I. Nigel et al. study that did not established
negative impact of delays on survival, total number of
delayed days was lower than ten days in a significant
part of patients [13].
Neutropenia was the main reason for chemotherapy de-
lays and platinum dose reduction (37.5%). Neutropenia-
related complications often demands not only specific
treatments but also chemotherapy scheme modifications:
prospective cohort study published in 2014 showed that
60% of patients with stage IV solid tumors needed RDI
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8% of all participants of this study [20]. Eisenhauer et al.
presented the following reasons for chemotherapy scheme
modifications in patients with stage IIIC-IV ovarian can-
cer: myelosuppression was the main reason in patients
under 65 years, and poor performance status was the main
reason in patients over 65 years. Chemotherapy scheme
modification because of poor performance status was ob-
served in 5.6% of all modifications made in our study [21].
Our data showed that 25.0% of chemotherapy scheme
modifications was not clinically grounded. This was speci-
fied as modification with no objective medical reason, and
this notion involves various social circumstances, trans-
portation issues interfering patient’s admission at sched-
uled date, and unmotivated doctor’s decision to reduce
recommended dose. We failed to prove statistically signifi-
cant negative impact of these factors on overall survival of
patients in our study.
Small subject population is limitation of this retro-
spective study. Possible variations of further treatment
were not taken into account and this could affect results
of patients survival. This study also had advantages: all
patients were treated in the same healthcare institution,
same methods of examination, initial treatment and
follow-up were applied and discrepancies in medical
documentation were avoided. Considering that only few
similar studies were carried out, findings of our study
are useful in clinical practice when chemotherapy
scheme individualization is necessary. Results of our
study will also be important in future: these are histor-
ical data worth to review when new systemic treatment
or surgery innovations emerge. However, larger pro-
spective studies are needed in order to obtain more ac-
curate and reliable results.Conclusions
Results of our study showed that chemotherapy delays
when treating patients diagnosed with FIGO stage III
ovarian cancer were associated with lower overall sur-
vival. According to our study, the most common reason
for platinum dose reduction or chemotherapy delays was
neutropenia.
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